放射線皮膚炎研究におけるフラーレン：エビデンス、製剤化、および安全性の境界

放射線皮膚炎における フラーレンの研究は 実験室段階の理論を超えて進展している。前臨床研究では、放射線照射された細胞や動物皮膚における水酸化フラーレン（フラーレノール）が調査され、一方、2025年および2026年に発表されたランダム化臨床試験では、放射線治療を受ける患者においてフラーレン含有外用クリームが評価された。.

結果は有望である。報告された研究では、フラーレン含有製剤は、急性放射線皮膚炎のグレードまたは発生率の低下、皮膚反応の発現遅延、疼痛の軽減、または臨床的に有意な皮膚炎の期間短縮と関連していた。.

しかしながら、これらの知見は、未修飾フラーレンC60、すべてのフラーレン誘導体、またはすべての市販フラーレンクリームが放射線照射皮膚に対して安全かつ有効であることを確立するものではない。エビデンスは、特定の完成品製剤、投与スケジュール、患者集団、比較対照、および研究プロトコルに適用される。.

したがって、中心的な科学的疑問は、単にフラーレンが活性種を捕捉できるかどうかではない。それは、精密に特性評価されたフラーレン材料を、放射線照射またはバリア障害のある皮膚に対して追加のリスクを生じさせることなく、安定で忍容性が高く、臨床評価された外用製品に製剤化できるかどうかである。.

本稿では、現在のエビデンスを概説し、未修飾C60とフラーレノールおよび完成品クリームを区別し、最も重要な製剤変数を検討し、研究者、製剤化担当者、サプライヤー、および患者が越えるべきでない境界を定義する。.

医学的注意事項： 本稿は、科学的、製剤的、および調達上の参考のみを目的とする。医学的アドバイスを提供するものではなく、自己治療を推奨するものでもない。放射線治療を受けている患者は、放射線腫瘍科チームが提供するスキンケアプロトコルに従うべきである。.

放射線皮膚炎とは何か？

放射線皮膚炎は、放射線治療中に照射される電離放射線によって引き起こされる皮膚反応である。急性放射線皮膚炎は、治療中または治療直後に発症する可能性があり、紅斑、乾燥、そう痒、不快感、落屑、疼痛、または湿性落屑として現れることがある。重症度は、放射線量、分割照射法、治療部位、併用療法、患者特性、皮膚のひだ、摩擦、およびその他の臨床的要因に依存する。.

電離放射線は、細胞DNAとの直接的な相互作用、および活性酸素種を介した間接的なプロセスを通じて皮膚に損傷を与える可能性がある。分割放射線治療中の反復曝露は、基底ケラチノサイト、炎症シグナル伝達、血管構造、毛包、および皮膚バリアに影響を及ぼす可能性がある。.^[1]

現在の支持療法戦略には、穏やかな洗浄、保湿、局所コルチコステロイド、バリアフィルム、被覆材、および治療部位、皮膚炎グレード、施設プロトコル、臨床医の評価に応じて選択されるその他の介入が含まれる場合がある。.^[2]

すべての患者または放射線皮膚炎のすべての段階に適した単一の介入は存在しない。これが、フラーレン含有製剤が研究されている臨床的状況である。.

なぜフラーレンが研究されているのか？

科学的根拠は酸化ストレスに焦点を当てている。フラーレン材料の共役炭素ケージは、電子移動およびラジカル関連反応に関与することができる。水酸化フラーレン誘導体は、実験室系において活性酸素種および窒素種の捕捉剤として研究されてきた。.

フラーレノールは特に重要である。なぜなら、フラーレンケージに結合した水酸基により、未修飾C60と比較して水との適合性が向上するからである。これにより、研究者は生物学的試験により実用的な水系またはエマルション系を調製することが可能になる。.

細胞および動物研究において、フラーレノール製剤は、照射後の細胞内活性酸素種、DNA損傷、アポトーシス、表皮肥厚、コラーゲン沈着、および皮膚付属器への損傷を低減することが報告されている。.^[3][4]

これらの知見は、さらなる研究のための妥当なメカニズムを提供する。しかし、すべての局所フラーレン製剤が患者において同じ効果を生み出すことを証明するものではない。.

実験室アッセイにおける分子のラジカル捕捉活性は、製品性能の一部に過ぎない。臨床結果は、関連する皮膚層への送達、濃度、滞留時間、製剤ビヒクル、安定性、忍容性、放射線スケジュール、患者アドヒアランス、および皮膚バリアの状態にも依存する。.

“「フラーレン」は互換性のある単一の材料ではない

最も重要な安全性および解釈上の問題の一つは用語である。研究論文や商業ページでは、「フラーレン」という用語が実質的に異なる材料を説明するために使用されることがある。.

材料タイプ	基本説明	製剤上の関連性
未修飾フラーレンC60	60個の炭素原子からなる未修飾の炭素ケージ	水に不溶性であり、適切な溶媒、分散剤、担体、または処理方法を必要とする
フラーレン C70	70個の炭素原子からなる細長い炭素ケージ	C60とは異なる分子、光学、および製剤特性を有する
フラーレノール	複数の水酸基を有する水酸化フラーレン	通常、より水との適合性が高く、放射線防護研究で広く使用される
カプセル化または担体結合フラーレン	脂質、ポリマー、界面活性剤、またはその他の担体システムに組み込まれたフラーレン	担体組成が安定性、浸透性、および忍容性を制御する可能性がある
完成品フラーレンクリーム	フラーレン関連材料および添加剤を含む多成分局所製剤	臨床エビデンスは、フラーレン成分単独ではなく、試験された完全な製品に適用される

水酸化フラーレノールからのエビデンスは、未修飾C60粉末に自動的に適用することはできない。ある完成品クリームからのエビデンスは、異なるフラーレン化学、濃度、乳化剤、保湿剤、保存料、または浸透促進剤を有する別のクリームに自動的に適用することはできない。.

この区別は、科学出版物、マーケティング資料、調達協議、および規制当局への提出書類全体を通じて維持されるべきである。.

現在のエビデンスの概要

エビデンス段階	研究	主な知見	重要な制限事項
細胞および材料研究	Zhaoら、2021年	スケーラブルなフラーレノール材料は、実験系においてラジカル消去能と皮膚放射線防護能を示した	前臨床エビデンスは臨床的有効性を確立するものではない
細胞およびマウス研究	Yinら、2023年	局所適用フラーレノールは、マウスにおける放射線誘発皮膚損傷の複数の兆候を軽減した	動物の皮膚とヒトの放射線治療は同等ではない
乳がん無作為化研究	Wangら、2025年	フラーレンクリームは、より低いARDグレード、発症遅延、疼痛軽減、およびより良好な報告された生活の質と関連していた	小規模、単一施設、非盲検試験；最終解析に81名の患者が含まれた
第II相頭頸部がん試験	Liuら、2026年	フラーレンクリームは、トロラミンと比較して、グレード2以上およびグレード3以上のARDを減少させた	単一施設および製品特異的；より広範な再現と長期的エビデンスが依然として必要である

前臨床エビデンスが示すもの

2021年の研究では、フリーラジカル消去活性を持つフラーレノールのスケーラブルな製造経路が記載され、その皮膚放射線防護能が調査された。.^[3]

その後の2023年の研究では、放射線照射されたケラチノサイト、線維芽細胞、および放射線皮膚炎のマウスモデルにおいて、局所適用フラーレノールが評価された。研究者らは、細胞モデルにおける細胞内活性酸素種の減少、DNA損傷およびアポトーシスの低減、ならびにマウスにおける複数の皮膚損傷指標の改善を報告した。.^[4]

マウス研究ではまた、表皮肥厚、コラーゲン沈着、および皮膚付属器損傷の減少が報告された。これらの結果は、局所フラーレノール研究の生物学的妥当性を支持する。.

それにもかかわらず、前臨床所見にはいくつかの限界がある：

• マウスの皮膚は、厚さ、毛密度、免疫応答、治癒、および曝露条件においてヒトの皮膚とは異なる。.
• 実験的な放射線量および治療領域は、臨床的な分割スケジュールを再現しない可能性がある。.
• フラーレン誘導体、濃度、基剤、および適用プロトコルは、後の臨床製品とは異なる可能性がある。.
• 組織学的改善は、患者報告による利益または長期的安全性を自動的に確立するものではない。.

前臨床結果は臨床研究を正当化する。それら自体を臨床的証明として提示すべきではない。.

2025年乳がん無作為化研究

2025年に発表された無作為化対照試験では、乳がんの術後放射線治療を受ける女性に対し、局所フラーレン保湿修復クリームが評価された。.^[5]

88名の参加者が、フラーレンクリーム群とトロラミン含有比較対照群に均等に無作為化された。脱落および不完全な治療後、最終解析には81名の参加者が含まれた：フラーレン群41名、比較対照群40名。.

製品は、放射線治療開始から治療完了まで1日3回適用された。放射線治療終了時、フラーレン群には以下が含まれた：

• グレード0のARD患者11名；;
• グレード1のARD患者28名；;
• グレード2のARD患者2名；;
• グレード3またはグレード4のARDは報告されなかった。.

比較対照群では、グレード0が3名、グレード1が25名、グレード2が12名のARDであった。また、同研究では、皮膚炎の初発時期が遅いこと、治療後期の疼痛スコアが低いこと、およびSkindex-16生活の質結果における差異が報告された。.

これらの所見は臨床的に興味深いが、この研究には重要な制限がある。製品の特性が明らかに異なっていたため、参加者および研究者は盲検化されていなかった。試験は単一施設で実施され、比較的小規模なサンプルであり、1つの名称のある最終製剤のみが評価された。著者らはまた、提案された抗酸化メカニズムを確認する患者レベルの生物学的エビデンスの欠如と、より長期的な評価の必要性を指摘した。.

したがって、この研究はさらなる研究を支持する。試験された製品と他のフラーレンクリームとの同等性を確立するものではない。.

2026年第II相頭頸部がん試験

2026年に報告された第II相二重盲検無作為化試験では、非転移性頭頸部がんの根治的または補助的放射線治療を受ける132名の患者において、フラーレンクリームがトロラミンクリームと比較評価された。.^[6]

参加者は、放射線治療開始3日前から治療後14日まで、割り当てられた製品を1日3回適用した。主要評価項目は、グレード2以上の急性放射線皮膚炎の発生率であった。.

報告された所見は以下の通りである：

• グレード2以上のARDは、フラーレン群で34.8%、トロラミン群で83.3%発生した。.
• 調整後相対リスクは0.34であった。.
• グレード2以上のARDの期間中央値は、フラーレン群で14日、トロラミン群で28日であった。.
• グレード3以上のARDは、フラーレン群で6.1%、トロラミン群で40.9%発生した。.

軽度のアレルギー反応が、フラーレンクリーム投与患者3名、トロラミン投与患者2名で報告された。治療関連の重篤な有害事象は報告されなかった。.

この試験は、動物研究や非盲検パイロット試験よりも強力な臨床エビデンスを提供する。しかし、すべての疑問に答えているわけではない。単一施設で実施され、特定の製剤を1つの比較対照と評価し、特定の頭頸部がん患者集団に焦点を当てたものである。.

追加の多施設試験、独立した再現、他のエビデンスに裏付けられた介入との比較、より長い追跡調査、および透明性のある製剤特性評価が、エビデンスベースを強化するだろう。.

臨床エビデンスが確立するものと確立しないもの

The two clinical studies support a careful conclusion:

Specific fullerene-containing topical formulations have shown promising results for reducing or delaying acute radiation dermatitis in randomized studies.

They do not establish the following claims:

• All fullerene creams prevent radiation dermatitis.
• Pristine C60 powder can be applied directly to irradiated skin.
• Fullerene is superior to every guideline-supported intervention.
• Fullerene creams are approved medical treatments in every market.
• A raw-material purity percentage establishes finished-product safety.
• A cosmetic fullerene cream is suitable for oncology patients.
• Fullerene can be used on open or moistly desquamated skin without clinician assessment.

Clinical evidence is product-specific. If the exact fullerene material, concentration, carrier system, excipient composition, manufacturing controls, and application protocol are not equivalent, the results cannot be assumed to transfer.

Why Fullerene Formulation Matters

Formulation is not a secondary issue. It determines whether the fullerene material remains dispersed, reaches the target layer, changes during storage, causes irritation, or penetrates beyond the intended site.

Pristine C60 is not water-soluble

Unmodified C60 does not readily dissolve in water. A topical product containing pristine C60 therefore requires a carrier, solvent, oil phase, surfactant, encapsulation system, or controlled dispersion strategy.

A dark cream or suspension does not prove that the molecules are uniformly distributed. Aggregation can affect dose consistency, skin contact, stability, and biological behavior.

Fullerenols are chemically different

Hydroxylation increases water compatibility, but it also changes molecular composition, surface chemistry, size distribution, aggregation, and biological interactions.

“Fullerenol” should not be treated as a single fixed substance. The number and distribution of hydroxyl groups, residual salts, synthesis by-products, molecular heterogeneity, and analytical characterization can vary.

The vehicle affects penetration

A 2017 ex vivo study using pig skin and Franz diffusion cells found that C60 dispersed in a transcutol/isopropyl myristate system could permeate skin.^[7]

This does not prove harmful systemic exposure or clinical benefit. It demonstrates that penetration is formulation-dependent. A material that remains primarily on the surface in one vehicle may penetrate differently in another.

This becomes particularly important when irradiated skin has an impaired barrier.

The complete cream may influence the outcome

A finished cream contains more than the named active ingredient. Humectants, occlusives, emulsifiers, polymers, preservatives, lipids, penetration enhancers, and other ingredients may affect hydration, irritation, wound environment, product adherence, and clinical outcome.

A trial comparing two finished creams therefore tests the formulations as complete systems. It does not isolate the effect of the fullerene molecule unless the study design and formulation controls specifically permit that conclusion.

What a Research-Grade Formulation Program Should Define

A credible fullerene topical-development program should define and control at least the following variables.

Development Area	Questions to Resolve
材料の同一性	Is the material pristine C60, C70, fullerenol, a derivative, or a carrier-bound fullerene?
Chemical characterization	What is the molecular composition, hydroxylation degree, functional-group profile, and fullerene distribution?
Purity and impurities	Which analytical methods are used, and what residual solvents, metals, salts, carbon by-products, or synthesis reagents remain?
Particle and aggregate behavior	What are the size distribution, aggregation state, morphology, and stability in the finished formulation?
Concentration	What concentration is present, how is it verified, and does it remain uniform throughout storage and use?
Vehicle composition	Which oils, surfactants, emulsifiers, polymers, or penetration enhancers are present?
Product stability	Does light, oxygen, temperature, radiation exposure, or packaging alter the formulation?
Microbiological quality	Is the preservative system suitable for the container, use pattern, and intended skin condition?
Dermal safety	Have irritation, sensitization, photoreactivity, penetration, genotoxicity, and damaged-skin exposure been evaluated?
Clinical workflow	When is the product applied relative to radiotherapy, cleansing, dressings, and other topical treatments?

Raw-material documentation is necessary, but it is only the beginning. Finished-product safety and efficacy require formulation-specific testing.

Safety Boundaries for Fullerene Radiation-Dermatitis Research

Do not equate “antioxidant” with universally safe

Antioxidant activity in a chemical assay does not establish dermal safety, clinical benefit, appropriate dose, or long-term outcome. Fullerene materials can behave differently depending on functionalization, aggregation, impurities, light exposure, and biological environment.

Do not extrapolate from intact skin to damaged skin

Radiated skin may become inflamed, dry, fissured, or desquamated. Barrier damage can change ingredient penetration and local tolerability. Testing performed on intact skin cannot automatically justify use on open or severely damaged areas.

Do not apply raw fullerene material directly

Laboratory Fullerene C60 powder is not a finished topical medical product. A COA and MSDS/SDS do not establish sterility, microbiological suitability, skin compatibility, dosing, or clinical efficacy.

Do not replace clinical skin-care protocols

Current radiation-dermatitis management includes evidence-based and consensus-supported interventions selected by clinical teams. Fullerene research should be interpreted within that supportive-care framework, not as a reason to discontinue prescribed skin care.^[2][8]

Do not ignore allergic reactions

The 2026 trial reported mild erythema, pruritus, or rash in some participants receiving fullerene cream. The absence of serious treatment-related adverse events in one trial does not prove that reactions cannot occur in broader populations.

Do not use “medical grade” without a defined basis

“Medical grade,” “pharmaceutical grade,” “oncology grade,” and similar descriptions should not be used unless they correspond to a verified specification, regulated product category, validated manufacturing standard, and intended-use framework.

High-purity C60 raw material is not automatically a medical-grade finished ingredient or an approved radiation-dermatitis treatment.

How Current Guidelines Should Be Interpreted

The 2023 MASCC systematic review and consensus recommendations evaluated a wide range of interventions for preventing and managing acute radiation dermatitis.^[1][2]

Fullerene was not included as a recommended standard intervention because the major human trials discussed in this article were published later. This creates an evidence-timing issue: newer trials may be promising, but guideline incorporation normally requires expert review, replication, comparison with existing interventions, feasibility assessment, and ongoing safety evaluation.

It is therefore inaccurate to say either that fullerene has no clinical evidence or that fullerene has already become universal standard care.

The defensible position in 2026 is:

Fullerene-containing topical formulations represent an emerging radiation-dermatitis research direction supported by preclinical work and two encouraging randomized clinical studies, but broader clinical validation and guideline evaluation are still required.

Implications for Researchers and Formulation Developers

The available results create a credible case for further development, particularly in the following areas:

• multicenter randomized trials;
• independent replication outside the original research groups;
• comparison with topical corticosteroids, barrier films, dressings, and other guideline-supported strategies;
• dose-response and application-frequency studies;
• standardized fullerene and fullerenol characterization;
• damaged-skin penetration and systemic-exposure evaluation;
• long-term safety and late skin-reaction follow-up;
• analysis by radiation site, dose, concurrent chemotherapy, skin type, and patient risk factors;
• identification of which formulation components contribute to clinical effects;
• regulatory classification in different markets.

Future publications should report the fullerene chemistry and finished formulation in enough detail to support scientific reproduction. Simply stating that a product “contains fullerene” is not sufficient.

Implications for Raw-Material Procurement

Research teams sourcing fullerene for formulation development should separate raw-material qualification from finished-product qualification.

Raw-material evaluation may include:

• product identity;
• molecular formula and CAS number where applicable;
• purity and analytical method;
• batch-specific COA;
• MSDS/SDS;
• residual solvent and impurity information when available;
• storage and packaging conditions;
• batch consistency;
• sample availability.

These documents do not establish that the material is suitable for direct use on patients. The formulation developer remains responsible for selecting the fullerene form, preparing the delivery system, conducting toxicology and stability studies, defining the intended use, and following the appropriate clinical and regulatory pathway.

結論

Research on fullerene in radiation dermatitis has advanced substantially. Fullerenol studies established a preclinical rationale based on oxidative-stress mitigation, and randomized studies published in 2025 and 2026 reported meaningful reductions in acute radiation-dermatitis outcomes with specific fullerene-containing creams.

The evidence is promising but still bounded. It is based on particular products, patient groups, application schedules, and study centers. It does not justify treating raw C60, fullerenol, cosmetic fullerene products, and clinically tested creams as interchangeable.

The decisive issue is not the fullerene name alone. It is the complete chain of material identity, chemical characterization, purity, dispersion, vehicle design, stability, skin penetration, tolerability, clinical evidence, manufacturing quality, and regulatory control.

For researchers, fullerene represents a credible emerging platform for topical radioprotection research. For patients, use should remain under the direction of the radiation oncology team. For suppliers and formulators, careful documentation and evidence boundaries are more important than aggressive medical claims.

FAQ

放射線皮膚炎に対するフラーレンの臨床的エビデンスは存在しますか？

はい。2025年および2026年に発表されたランダム化試験では、特定のフラーレン含有クリームにより急性放射線皮膚炎の重症度・発生率の低減、発症の遅延、または持続期間の短縮が報告されています。ただし、このエビデンスは製品固有のものであり、より広範な再現性が求められます。.

フラーレンは現在、放射線皮膚炎に対する標準的なガイドライン治療として位置づけられていますか？

いいえ、フラーレンは2023年のMASCCガイドラインにおいて標準推奨介入として含まれていませんでした。重要なフラーレンの臨床試験はその後発表され、現在もより広範なレビューと検証が必要です。.

フラーレノールは、未修飾のフラーレンC60と同じものですか？

いいえ。フラーレノールは水溶性や表面化学的特性が異なる水酸化フラーレン誘導体であり、フラーレノールを用いて得られた知見を、未修飾のC60にそのまま適用すべきではありません。.

未加工のフラーレンC60粉末を、放射線照射を受けた皮膚に適用することは可能ですか？

いいえ。未加工のフラーレンC60は研究用または工業用材料であり、完成された局所用製品ではありません。照射された皮膚への直接塗布に向けて、製剤化、用量設定、保存、または臨床評価は行われていません。.

フラーレンの臨床試験において、有害反応は報告されましたか？

2026年第II相試験では、紅斑、掻痒、または発疹を含む軽度のアレルギー反応が数名の参加者に認められた。治療に関連する重篤な有害事象は報告されなかったが、より広範な使用において反応が生じる可能性が否定されるものではない。.

フラーレンの抗酸化活性は、放射線皮膚炎を予防することを証明していますか？

いいえ。抗酸化作用および活性種消去活性は機構的な根拠を提供しますが、臨床成績は製剤、用量、浸透性、安定性、患者因子、および放射線治療条件にも依存します。.

フラーレン局所製剤は何を開示しなければならないか？

信頼性のある開発プログラムでは、フラーレンの種類、化学的特性、純度、濃度、凝集状態、媒体、添加剤、安定性、微生物学的品質、皮膚安全性、浸透挙動、ならびに意図された適用プロトコルを定義すべきである。.

バッチ固有のCOAは、C60が臨床的に安全であることを証明するものですか？

いいえ。COA（分析証明書）は原材料の識別とバッチ品質を保証するものです。完成品の皮膚に対する安全性、無菌性、臨床的有効性、規制当局の承認、または損傷した皮膚への適用適合性を証明するものではありません。.

CTA

Developing a fullerene formulation for controlled laboratory, preclinical, or formulation research?

The Fullerene can provide research-use Fullerene C60 information, available purity options, batch-specific COA, MSDS/SDS, sample availability, packaging details, and storage guidance.

Raw Fullerene C60 is not supplied as a finished radiation-dermatitis treatment and should not be applied directly to patients or irradiated skin.

Review Fullerene C60 material information または submit your research material requirement with target purity, quantity, formulation context, destination country, and required documentation.

参考文献

[1] Behroozian T, Goldshtein D, Ryan Wolf J, et al. “MASCC clinical practice guidelines for the prevention and management of acute radiation dermatitis: part 1, systematic review.” EClinicalMedicine. 2023;58:101886. 出典

[2] Behroozian T, Bonomo P, Patel P, et al. “Multinational Association of Supportive Care in Cancer clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recommendations.” The Lancet Oncology. 2023;24:e172–e185. 出典

[3] Zhao M, Wang C, Xie J, Ji C, Gu Z. “Eco-Friendly and Scalable Synthesis of Fullerenols with High Free Radical Scavenging Ability for Skin Radioprotection.” Small. 2021;17:e2102035. 出典

[4] Yin H, Gao Y, Chen W, et al. “Topically applied fullerenols protect against radiation dermatitis by scavenging reactive oxygen species.” Discover Nano. 2023;18:101. 出典

[5] Wang Q, Shi X, Guo J, et al. “Topical EOSSKY fullerene moisturizing and repairing cream for preventing acute radiation dermatitis in breast cancer patients undergoing radiotherapy: a randomized controlled trial.” Frontiers in Medicine. 2025;12:1604012. 出典

[6] Liu Z, et al. “Fullerene for Reducing Acute Radiation Dermatitis in Patients Undergoing Radiotherapy for Head and Neck Cancer: A Phase II, Double-Blind, Randomized Controlled Trial.” Journal of Clinical Oncology. 2026. 出典

[7] Martins M, Azoia NG, Melle-Franco M, Ribeiro A, Cavaco-Paulo A. “Permeation of skin with C60 fullerene dispersions.” Engineering in Life Sciences. 2017;17:732–738. 出典

[8] eviQ. “Radiation-induced dermatitis.” Clinical guidance on preventive skin care and management of radiation-induced skin reactions. 出典

[9] Kazmierska-Grebowska P, et al. “Nanotechnology meets radiobiology: Fullerenols and metallofullerenols as nano-shields in radiotherapy.” Biomedicine & Pharmacotherapy. 2025;117915. 出典

Radiation dermatitis is a clinically important adverse effect of radiotherapy, but that fact does not make every antioxidant-related topical material an established treatment. Fullerene C60 and functionalized fullerene materials have been investigated in skin, oxidative-stress and photobiology research. These studies provide hypotheses for further investigation; they do not by themselves establish that a C60 cream prevents or treats radiation dermatitis.

A defensible evaluation must separate four different questions: whether a fullerene material shows an effect in a chemical or cell model, whether a finished topical formulation is stable and biologically appropriate, whether controlled clinical research demonstrates patient benefit, and whether the finished product meets the regulatory requirements for its intended market and claims. Evidence at one level cannot replace evidence at the others.

放射線皮膚炎とは何か？

Radiation dermatitis describes skin reactions that occur in connection with exposure to therapeutic ionizing radiation. Clinical appearance and severity vary with accumulated skin dose, fractionation, treatment site, field geometry, concurrent systemic therapy, patient factors and the timing of assessment.

Possible manifestations include erythema, dryness, itching, discomfort, desquamation and, in more severe cases, substantial disruption of the skin barrier. Acute and late reactions must also be distinguished. A product studied for mild erythema cannot automatically be assumed suitable for moist desquamation, ulceration, infection risk or chronic radiation injury.

The US National Cancer Institute maintains the Common Terminology Criteria for Adverse Events, or CTCAE, as a standardized framework for recording adverse events in oncology trials.^[1] Any comparative study claiming to reduce radiation dermatitis should identify the grading system and define exactly which grade, time point and anatomical assessment produced the reported outcome.

Why Fullerenes Are Considered for Skin Research

Fullerene C60 is a closed molecular carbon cage with electron-accepting and photochemical properties. The cage can also be functionalized, creating derivatives with different polarity, aggregation, charge and interaction with biological systems. For background on the underlying molecule, see フラーレンC60とは何か.

Fullerene materials are studied in oxidative-stress research because their electronic structure can participate in radical-related chemistry. However, terms such as “antioxidant” and “radical scavenger” do not define a universal biological response. Depending on chemical structure, aggregation, solvent, oxygen, concentration and light exposure, a fullerene system may participate in different photochemical and redox processes.

This duality matters for irradiated skin. An effect observed in a cell-free radical assay does not show that the same material will penetrate appropriately, remain stable, avoid sensitization, preserve normal cellular signalling or improve a clinically meaningful outcome in patients undergoing radiotherapy.

Pristine C60 Is Not the Same as a Fullerene Cream

Pristine C60 powder, a functionalized fullerene and a formulated topical product are three different test articles. A finished cream also contains an oil or aqueous phase, emulsifiers, preservatives, antioxidants, viscosity modifiers and packaging-contact materials. These components can affect fullerene dispersion, chemical stability, skin delivery and photochemical behavior.

A statement such as “contains 99.95% C60” describes the fullerene starting material only if the percentage has been determined by an appropriate method. It does not mean that the finished cream contains 99.95% C60, that all particles have a defined size, or that the formulation has been shown to be safe on damaged skin.

Topical fullerene research should define at least:

• the exact fullerene or derivative;
• the analytical method used to establish identity and purity;
• the concentration in the finished formulation;
• whether the material is dissolved, molecularly associated, dispersed or aggregated;
• particle or aggregate characteristics where relevant;
• the complete vehicle and preservation system;
• light, oxygen and temperature stability; and
• the intended condition of the skin barrier.

Without this information, results cannot be reproduced reliably or transferred to another product.

Why the Existing Clinical Statistics Should Be Removed

The previous version of this page reported that a fullerene cream reduced Grade 2 or higher acute radiation dermatitis from 83.3% to 34.8%, reduced Grade 3 reactions from 40.9% to 6.1%, and shortened severe symptoms from 28 days to 14 days. During the present review, no original peer-reviewed paper, registered trial record or authoritative clinical report supporting these exact comparisons could be verified.

Precise percentages create the appearance of high-quality clinical evidence, but the numbers are not interpretable without their source and study design. Necessary information would include participant numbers, cancer and treatment sites, radiation regimens, allocation method, blinding, comparator composition, baseline risks, attrition, grading criteria, assessment schedule, adverse events and statistical analysis.

Until a primary source containing those data is available and reviewed, the figures should not appear in The Fullerene’s public content. They also should not be used in sales presentations, product descriptions, social media posts or distributor materials.

What Evidence Would Support a Clinical Claim?

A credible clinical-development pathway begins with a chemically defined and stable finished formulation. Nonclinical testing should reflect the proposed use, including topical exposure and the condition of the skin barrier. A formulation intended for intact skin cannot automatically be applied to moist desquamation or open lesions.

A controlled clinical study would then need a prespecified protocol, an appropriate comparator and validated outcome assessment. Radiation dermatitis should be graded using an identified system such as CTCAE or another established oncology scale. Patient-reported pain, itching, quality of life, treatment interruption and infection may also be relevant, but endpoints must be defined before results are examined.

Evidence-based radiation-dermatitis guidance evaluates interventions through systematic review rather than assuming that an antioxidant mechanism predicts clinical efficacy.^[2] A new fullerene formulation would have to demonstrate benefits and risks within that clinical context.

Why a before-and-after comparison is insufficient

Skin reactions change during and after radiotherapy. Apparent improvement may reflect the treatment schedule, natural recovery, changes in skin care, dose distribution or differences between patients. Without an appropriate control group and consistent assessment, improvement cannot confidently be attributed to the fullerene formulation.

Why formulation-specific evidence is necessary

Even if one fullerene cream eventually demonstrates a clinical effect, that result would apply first to the tested formulation. It would not validate every cream made from C60 powder, every fullerene derivative or every concentration. Changes in vehicle, preservative, fullerene source, particle characteristics or packaging could change performance and safety.

Skin Barrier Disruption Changes the Safety Question

Normal intact skin is an important protective barrier. Irradiated skin may become inflamed, fragile or disrupted. Consequently, exposure and tolerability data obtained on healthy intact skin may not describe use on clinically significant radiation dermatitis.

Applying a nanomaterial formulation to compromised skin raises questions involving local irritation, sensitization, penetration, systemic availability, microbial contamination and interaction with wound-care products. These questions cannot be resolved by describing the raw C60 as “high purity.”

The previous page stated that a fullerene cream could be used on open radiotherapy wounds if it contained “pharmaceutical-grade, zero heavy metal residue” C60. That statement should be deleted. No raw-material purity grade alone authorizes application to an open wound or demonstrates that a finished formulation is sterile, biocompatible, clinically effective or approved for that indication.

What the SCCS Opinion Means

In its final opinion on fullerenes, hydroxylated fullerenes and hydrated forms of hydroxylated fullerenes used as cosmetic nanomaterials, the European Commission’s Scientific Committee on Consumer Safety concluded that it could not determine safety because of substantial physicochemical, toxicokinetic and toxicological data gaps.^[3]

The SCCS specifically stated that it could not exclude the genotoxic potential of C60 and C70. It also identified concerns involving impurities, organic solvents, stability, radical generation, phototoxicity, sensitization, dermal absorption, systemic availability and possible organ accumulation.

This opinion does not prove that all fullerene formulations are unsafe. It does mean that a supplier should not claim that SCCS requirements have already been satisfied simply because a fullerene raw material has a high HPLC percentage or selected metals were not detected.

The opinion also concerns cosmetic use. A product marketed to prevent or treat radiation dermatitis may fall outside an ordinary cosmetic positioning because the claim relates to a treatment-associated medical condition. Classification depends on the jurisdiction, intended use, claims, composition and mode of action.

Why “Medical-Grade” and “Pharmaceutical-Grade” Require Evidence

Terms such as “medical-grade C60” and “pharmaceutical-grade fullerene” should not be used as independent proof of suitability. A grade designation is meaningful only when connected to an actual specification, recognized compendial standard, validated manufacturing controls or a defined regulatory framework.

There is no universal fullerene specification under which any sufficiently pure C60 powder automatically becomes approved for medicines, radiation wounds or oncology skin care. The intended finished product determines which quality, nonclinical, clinical and manufacturing requirements apply.

The same applies to “zero heavy metals.” Analytical chemistry can establish that selected elements were not detected above stated limits under a defined method. It cannot establish absolute absence. More importantly, elemental analysis addresses only one part of product safety.

Why ICH Q3D Does Not Prove Topical Fullerene Compliance

ICH Q3D provides a risk-based framework for elemental impurities in drug products.^[4] It does not certify fullerene raw materials, approve C60 creams or establish that an oncology skin formulation is safe for open wounds.

Using Q3D in a pharmaceutical-development program would require an assessment of the actual drug product, route of administration, sources of elemental impurities and applicable limits. A supplier cannot infer finished-product compliance from a general statement that its synthesis process avoids selected metal catalysts.

HPLC analysis of fullerene species also cannot replace elemental testing. Conversely, an elemental report cannot establish C60 identity, residual solvents, oxidation products, microbiological quality or finished-product performance. The guide to C60 HPLC純度分析 explains this analytical boundary in more detail.

Research Questions That Remain Scientifically Valuable

Removing unsupported treatment claims does not mean fullerene skin research lacks value. Several research questions remain appropriate:

• How do defined fullerene structures behave in skin-relevant oxidative and photochemical models?
• How do vehicle, concentration and aggregation affect skin interaction?
• Does ionizing-radiation exposure alter the fullerene or the finished formulation?
• What degradation products form during realistic storage and use?
• How does intact-skin exposure differ from barrier-disrupted models?
• Which analytical methods can track fullerene identity in complex creams?
• Can a fully characterized formulation demonstrate benefit in a controlled clinical study without creating unacceptable risks?

These are formulation, toxicology and clinical-research questions. They should be investigated through defined materials and appropriate study systems rather than answered through general statements about C60’s molecular structure.

How Research Teams Should Specify Fullerene Starting Material

A research team developing a topical fullerene system may need to define fullerene identity, chromatographic profile, residual solvents, elemental impurities, water content, oxidation history and packaging. The necessary information depends on the formulation and development stage.

Starting-material documentation supports experimental control; it does not guarantee a therapeutic result. Finished-product testing must still evaluate how the fullerene behaves after incorporation into the complete formulation.

The Fullerene, supported by a globally respected scientific research network, supplies C60 and C70 materials representing a leading level of fullerene production in Asia. XCT can support technically defined material evaluation while maintaining a clear boundary between supplying research materials and claiming an unverified medical outcome.

Discuss a Fullerene Formulation Research Requirement

Research teams studying fullerene stability, topical formulation or skin-related material systems may contact XCT with the intended test system, fullerene identity, required purity and analytical needs. The Fullerene does not present pristine C60 powder as an approved treatment for radiation dermatitis.

The Fullereneに連絡する

よくある質問

Is fullerene cream an approved treatment for radiation dermatitis?

No verified evidence reviewed for this article establishes fullerene cream as an approved or standard treatment for radiation dermatitis. Any clinical use would require formulation-specific evidence and the applicable regulatory authorization.

Can high-purity C60 be applied directly to irradiated or open skin?

No. Raw C60 purity does not establish that a material is suitable for direct topical use, damaged skin or open wounds. A finished formulation requires separate safety, quality and clinical evaluation.

Does antioxidant activity prove that C60 will prevent radiation skin injury?

No. Chemical or laboratory antioxidant activity is mechanistic evidence, not proof of clinical prevention or treatment. Biological behavior depends on fullerene structure, formulation, concentration, light and the test system.

Does a metal test make a fullerene cream medically compliant?

No. Elemental testing addresses selected impurities only. It does not establish fullerene identity, formulation stability, sterility, biocompatibility, clinical efficacy or regulatory approval.

What is an appropriate role for C60 in radiation dermatitis research?

C60 may be investigated as a defined research material in formulation, photochemistry, toxicology and controlled preclinical studies. Any progression to clinical use must be based on the finished formulation and an appropriate development program.

参考文献

1. US National Cancer Institute. “Common Terminology Criteria for Adverse Events and CTEP Trial Resources.” NCI source.
2. Behroozian, T. et al. “MASCC Clinical Practice Guidelines for the Prevention and Management of Acute Radiation Dermatitis: Systematic Review.” eClinicalMedicine, 2023. https://doi.org/10.1016/j.eclinm.2023.101886.
3. Scientific Committee on Consumer Safety. “Opinion on Fullerenes, Hydroxylated Fullerenes and Hydrated Forms of Hydroxylated Fullerenes (Nano).” SCCS/1649/23, final version adopted October 26, 2023. 欧州委員会PDF.
4. International Council for Harmonisation. “ICH Q3D(R2): Guideline for Elemental Impurities.” ICH guideline.
5. US Food and Drug Administration. “Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?).” FDAソース.
6. US Food and Drug Administration. “Guidance for Industry: Safety of Nanomaterials in Cosmetic Products.” FDA guidance.